- Home
- VTLE vs TRVI Comparison
VTLE vs TRVI Comparison
Compare VTLE & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTLE
- TRVI
- Stock Information
- Founded
- VTLE 2006
- TRVI 2011
- Country
- VTLE United States
- TRVI United States
- Employees
- VTLE N/A
- TRVI N/A
- Industry
- VTLE
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- VTLE
- TRVI Health Care
- Exchange
- VTLE Nasdaq
- TRVI Nasdaq
- Market Cap
- VTLE 640.1M
- TRVI 725.7M
- IPO Year
- VTLE 2011
- TRVI 2019
- Fundamental
- Price
- VTLE $18.58
- TRVI $7.87
- Analyst Decision
- VTLE Hold
- TRVI Strong Buy
- Analyst Count
- VTLE 11
- TRVI 9
- Target Price
- VTLE $26.75
- TRVI $19.94
- AVG Volume (30 Days)
- VTLE 1.2M
- TRVI 1.9M
- Earning Date
- VTLE 08-06-2025
- TRVI 08-07-2025
- Dividend Yield
- VTLE N/A
- TRVI N/A
- EPS Growth
- VTLE N/A
- TRVI N/A
- EPS
- VTLE N/A
- TRVI N/A
- Revenue
- VTLE $1,982,155,000.00
- TRVI N/A
- Revenue This Year
- VTLE $3.16
- TRVI N/A
- Revenue Next Year
- VTLE N/A
- TRVI N/A
- P/E Ratio
- VTLE N/A
- TRVI N/A
- Revenue Growth
- VTLE 16.77
- TRVI N/A
- 52 Week Low
- VTLE $12.30
- TRVI $2.36
- 52 Week High
- VTLE $44.94
- TRVI $8.11
- Technical
- Relative Strength Index (RSI)
- VTLE 56.30
- TRVI 74.32
- Support Level
- VTLE $16.56
- TRVI $6.67
- Resistance Level
- VTLE $17.62
- TRVI $8.11
- Average True Range (ATR)
- VTLE 1.07
- TRVI 0.41
- MACD
- VTLE 0.12
- TRVI 0.17
- Stochastic Oscillator
- VTLE 83.59
- TRVI 89.66
About VTLE Vital Energy Inc. par value $0.01 per share
Vital Energy is an independent energy company. Its business is focused on the acquisition, exploration, and development of oil and natural gas properties in the Permian Basin of West Texas. The Company has identified one operating segment: exploration and production.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.